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Response to Negenborn et al, 2018: Quality of life and patient satisfaction after one-stage 
implant-based breast reconstruction with an acellular dermal matrix versus two-stage breast 
reconstruction (BRIOS): primary outcome of a randomised, controlled trial 
https://doi.org/10.1016/S1470-2045(18)30378-4 
Dear Sirs, 
We read with great interest the latest results from the BRIOS1 randomised controlled trial of one-stage 
versus two-stage implant-based breast reconstruction (IBBR). We would like to congratulate the authors 
for publishing the primary outcome of the study. 
Although implant loss rates were significantly higher in patients receiving single-stage mesh-assisted 
direct-to-implant reconstruction than those undergoing two-stage expander-implant procedures (29% 
versus 7%), there were no significant differences in patient satisfaction between the groups irrespective 
of whether those with complications were included in the analysis. 
Two potential hypotheses could explain these findings. 
Firstly, the primary outcome was assessed at 17 months following placement of the definitive implant 
rather than at one year as planned.  Reasons for this are unclear but notably almost all (18/21) patients 
who experienced implant loss in the BRIOS study went on to have secondary reconstruction within the 
study period.  Did the seven-month delay therefore reflect the need for additional surgery and the time-
frame for achieving a successful reconstruction?  May this also explain why complications do not appear 
to impact patient satisfaction as patients with a successful reconstruction were satisfied with the end-
result, irrespective of how it was achieved?  This is an important finding and would be consistent with 
findings from the National Mastectomy and Breast Reconstruction Audit that suggest that short-term 
implant-based complications do not affect longer-term quality of life2.  Complications, however, are likely 
to impact patients’ short-term well-being and longitudinal assessment of patient satisfaction may be a 
more appropriate method for assessing the true impact of an intervention; an important learning-point 
for future studies. 
The apparent discrepancy in contralateral symmetrisation surgery performed in the two groups may be 
another contributory factor. 20% (13/62) of the patients in the two-stage group underwent a 
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symmetrising procedure, but no symmetrising procedures were reported in the one-stage group.  Were 
patients “opportunistically” more likely to undergo contralateral surgery where a second-stage was 
planned?  
While the BRIOS study adds significantly to the evidence-base, we believe uncertainty remains 
regarding the role of acellular dermal matrix in IBBR.  We hope that the results of the iBRA study3 will  
help inform this debate.    
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